Company news
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) news
Every Acurx Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
August 17, 2026
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
August 14, 2026
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
August 12, 2026
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potent...
August 3, 2026
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. di...
July 14, 2026
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
July 8, 2026
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat
May 19, 2026
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
May 12, 2026
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
May 4, 2026
Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit
April 27, 2026
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
April 20, 2026
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 16, 2026
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 16, 2026
New to The Street Resigns Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) to Continue Long-Form Interview Series, Outdoor Media Campaigns and A...
April 7, 2026
Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
March 30, 2026
Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
March 13, 2026
Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Tr...
March 9, 2026
Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Busine...
February 16, 2026
USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
February 2, 2026
Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmac...
November 18, 2025
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
November 12, 2025
Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positiv...
November 10, 2025
Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity P...
October 28, 2025
Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update
October 27, 2025
Meet the Companies - New to The Street's Accredited Investor Event Returns October 21-22 at Hudson Yards, NYC
October 10, 2025
Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
October 9, 2025
Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection
September 30, 2025
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media,...
September 6, 2025
Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules
September 3, 2025
Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update
August 12, 2025
Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split
July 31, 2025
Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update
July 24, 2025
/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./
June 18, 2025
Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI
June 17, 2025
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol ...
June 9, 2025
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update
May 13, 2025
Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update
April 30, 2025
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
April 28, 2025
Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
April 17, 2025
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
March 18, 2025
Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering
March 10, 2025
Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering
March 7, 2025
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibio...
March 3, 2025
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Busine...
February 28, 2025
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat i...
February 24, 2025
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
February 19, 2025
Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)
January 6, 2025
Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
January 6, 2025
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025
December 11, 2024
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications
December 9, 2024